{
  "id": "6024a25c1cb411341a0000a1",
  "type": "summary",
  "question": "What is the role of elagolix in treatment of uterine fibroids?",
  "ideal_answer": "Elagolix is approved for the treatment of moderate to severe pain caused by endometriosis. Elagolix is also effective for heavy bleeding caused by uterine fibroids.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30194661",
    "http://www.ncbi.nlm.nih.gov/pubmed/30570832",
    "http://www.ncbi.nlm.nih.gov/pubmed/30774352",
    "http://www.ncbi.nlm.nih.gov/pubmed/28579415",
    "http://www.ncbi.nlm.nih.gov/pubmed/31695514",
    "http://www.ncbi.nlm.nih.gov/pubmed/31650182",
    "http://www.ncbi.nlm.nih.gov/pubmed/33045114",
    "http://www.ncbi.nlm.nih.gov/pubmed/29476499",
    "http://www.ncbi.nlm.nih.gov/pubmed/32702363",
    "http://www.ncbi.nlm.nih.gov/pubmed/31971678"
  ],
  "snippets": [
    {
      "text": "One of them, Elagolix, is in the early stages of testing in women with fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30774352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, elagolix received US FDA approval for the treatment of moderate to severe pain caused by endometriosis. Several clinical trials assessed the efficacy of elagolix for the treatment of heavy bleeding caused by UFs and the definitive results of Phase III studies are expected. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31695514",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476499",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain associated with endometriosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30194661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clinical development for heavy menstrual bleeding associated with uterine fibroids in the aforementioned locations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30194661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28579415",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION(S): Elagolix significantly reduced heavy menstrual bleeding in women with fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28579415",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31971678",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Elagolix with add-back therapy was effective in reducing heavy menstrual bleeding in women with uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31971678",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In Elaris Uterine Fibroids 1 and Uterine Fibroids 2, 2 replicate multicenter, double-blind, randomized, placebo-controlled, phase 3 studies, treatment of premenopausal women with elagolix with hormonal add-back therapy demonstrated reduction in heavy menstrual bleeding associated with uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32702363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix coadministered with estradiol/norethindrone acetate is in late-stage development for the management of heavy menstrual bleeding associated with uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elagolix is an oral gonadotropin-releasing hormone receptor antagonist indicated for the management of endometriosis-associated pain and in combination with estradiol/norethindrone acetate indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Ela",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine f",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In Elaris Uterine Fibroids 1 and Uterine Fibroids 2, 2 replicate multicenter, double-blind, randomized, placebo-controlled, phase 3 studies, treatment of premenopausal women with elagolix with hormonal add-back therapy demonstrated reduction in heavy menstrual bleeding associated with uterine fibroids.O",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32702363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " ovulation. In Elaris Uterine Fibroids 1 and Uterine Fibroids 2, 2 replicate multicenter, double-blind, randomized, placebo-controlled, phase 3 studies, treatment of premenopausal women with elagolix with hormonal add-back therapy demonstrated reduction in heavy menstrual bleeding associated with uterine fibroids.OBJECTIVE: This analysis aimed to evaluate the safety and efficacy of elagolix (300 mg twice a day) with add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day) in reducing heavy menstrual bleeding associated with uterine fibroids in various subgroups of women over 6 months of treatment.STUDY DESIGN: Data were pooled from Elaris Uterine Fibroid-1 and Uterine Fibroid-2 studies, which evaluated premenopausal women (18-51 years) with heavy menstrual bleeding (>80 mL menstrual blood loss per cycle, alkaline hematin methodology) and ultrasound",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32702363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids.OBJECTIVE: The objective was to evaluate the effects of elagolix on ovulation and ovarian sex hormones.DESIGN AND SETTING: This was a randomized, open-label, multicenter study.PARTICIPANTS: Participants were healthy ovulatory women aged 18 to 40 years.INTERVENTIONS: Elagolix was administered orally for 3 continuous 28-day dosing intervals at 100 to 200 mg once daily (QD), 100 to 300 mg twice daily (BID), and 300 mg BID plus estradiol/norethindrone acetate (E2/NETA) 1/0.5 mg QD.MAIN OUTCOME MEASURES: The main outcomes measures were ovulation rates measured by transvaginal ultrasound, progesterone conce",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650182",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Available data on elagolix and UFs showed that the drug, with or without low-dose hormone add-back therapy, is able to significantly reduce menstrual blood loss, lead to amenorrhea and improve haemoglobin concentrations in the majority of participants in comparison with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31695514",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}